Monkeypox Testing Market Size & Share 2024 – 2032

Monkeypox Testing Market Size

Monkeypox testing market size was valued at around USD 1.7 billion in 2023 and is estimated to grow at 4.5% CAGR from 2024 to 2032. Monkeypox testing refers to the diagnostic processes used to detect the presence of the monkeypox virus in an individual. Monkeypox is a viral zoonotic disease that is similar to smallpox, though generally less severe. Samples are collected from skin lesions, including swabs from the surface of the lesion or fluids from the vesicles and pustules. In some cases, throat swabs, blood, urine, or other bodily fluids may also be used.

The rising advancements in diagnostic research is a significant driver for the monkeypox testing market. For instance, according to the National Institutes of Health, in 2023, nucleic acid testing such as real-time PCR. It is considered the gold standard for diagnosing monkeypox, offering high sensitivity and specificity. Several real-time PCR assays have been developed for different targets in the monkeypox virus genome, providing a reliable means of detection.
 

Furthermore, increasing adoption of nucleic acid amplification testing, advancement in vaccines, increasing demand for self-testing, surging utilization of PCR technologies, government initiatives and funding, and increasing education & awareness, are the promoting factors advancing the growth of the market.

Monkeypox Testing Market Trends

The increasing prevalence of monkeypox cases is a significant driver for market. As cases rise, there is an urgent need to quickly identify and isolate infected individuals to prevent further spread. This drives the demand for reliable and rapid testing.
 

• According to the U.S. Department of Health & Human Services, in 2023, at total of 95,912 monkeypox cases were reported globally.
   
• Further, as per the same report, Brazil reported a surge in cases with 10,967 in 2023 along with 16 deaths. Thus, increased testing is crucial for monitoring and understanding the epidemiology of monkeypox, helping public health authorities track outbreaks and implement effective control measures.
   
• Healthcare systems need to be equipped to handle outbreaks that includes having sufficient testing capabilities. Increased prevalence necessitates enhanced testing infrastructure and capacity. With more cases healthcare providers must have access to accurate diagnostic tools to distinguish monkeypox from other diseases with similar symptoms, such as chickenpox and smallpox.
   
• Increased prevalence often leads to government funding and support for testing initiatives including grants for research and development of better diagnostic tools, thereby increasing the growth of the market.
   

Monkeypox Testing Market Analysis

Based on technology, the market is classified into polymerase chain reaction (PCR), lateral flow assay (LFA), and other technologies. The polymerase chain reaction (PCR) segment is estimated to account for USD 1.3 billion by 2032.

• PCR is known for its exceptional accuracy in detecting viral DNA, making it highly reliable for identifying monkeypox infections even at low viral loads. This level of precision is crucial for early diagnosis and effective disease management.
   
• Further, with the rapid advancement in PCR & NGS based diagnostic testing, the turnaround times for test results has increased often within a few hours. This rapid response is essential for timely public health interventions, patient management, and controlling the spread of the virus.
   
• It is a well-established and widely adopted technology in laboratories worldwide. Its familiarity among healthcare professionals and existing infrastructure for PCR testing facilitate its swift implementation for monkeypox testing.
   
• Thus, PCR technology is invaluable for epidemiological studies and surveillance, helping track the spread of monkeypox and monitor outbreak trends. Its application in research settings also supports the development of new diagnostic tools and treatments, thereby leading the segmental growth.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on mode, the monkeypox testing market is divided into laboratory testing and point of care testing. The laboratory testing segment accounted for USD 1.1 billion in 2023.
 

• Laboratory testing including PCR and other molecular diagnostics, offers high sensitivity and specificity, ensuring accurate detection of monkeypox virus. This accuracy is critical for confirming cases and guiding treatment decisions.
   
• Many laboratories have the necessary infrastructure, equipment, and trained personnel to conduct complex diagnostic tests. This established setup enables rapid implementation and scaling of monkeypox testing without significant additional investment.
   
• Moreover, laboratory testing is often subject to stringent regulatory standards, ensuring high-quality and reliable results. Regulatory compliance builds trust among healthcare providers and patients, supporting the widespread use of laboratory-based diagnostics.
   
• Laboratories can process a large number of samples simultaneously, making them essential during outbreaks when testing demand surges. High-throughput capabilities are crucial for timely diagnosis and public health response. Consequently, they play a vital role in epidemiological surveillance, helping track the spread of monkeypox, identify hotspots, and monitor outbreak trends.
   
• Thus, such aforementioned factors are expected to augment the segmental growth.
•  

Based on end use, the monkeypox testing market is segmented into hospitals and clinics, diagnostic laboratories, and other end-users. The hospitals and clinics segment held a market share of 47.7% in the year 2023.
 

• Hospitals and clinics provide immediate access to testing for patients who present with symptoms of monkeypox. This accessibility is crucial for early diagnosis and timely treatment, which helps in controlling the spread of the virus.
   
• These settings offer a range of medical services beyond testing, including patient consultation, treatment, and follow-up care. This comprehensive approach ensures that patients receive holistic care, from diagnosis to recovery.
   
• Patients often trust hospitals and clinics for medical testing and care. The credibility and established reputation of these institutions make them preferred locations for reliable and accurate monkeypox testing.
   
• Additionally, hospitals and clinics are integral parts of public health infrastructure. They work closely with public health authorities to report cases, monitor outbreaks, and implement control measures. This collaboration is essential for effective epidemic management, thereby escalating the growth of the market.
   

The U.S. monkeypox testing market is anticipated to grow at CAGR of 4.2% during the analysis timeframe.
 

• Increasing prevalence of monkeypox is a significant factor for the growth of the market. For instance, according to the National Library of Medicine, in 2023, there were 32,063 cases along with 38 deaths in the country.
   
• Further, 6,160 cases were reported in California alone. Thus, with a large and diverse population there is a significant demand for medical testing services. During outbreaks, the need for monkeypox testing rises sharply, contributing to the substantial market share.
   

Germany monkeypox testing market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The country has one of the most advanced healthcare systems in the world, with well-equipped laboratories and medical facilities capable of conducting high-volume and accurate monkeypox testing.
   
• Additionally, the country has a robust public health infrastructure, including institutions like the Robert Koch Institute (RKI), which plays a crucial role in disease surveillance, outbreak response, and coordination of testing efforts.
   

Japan monkeypox testing market is expected to grow significantly over the years.
 

• Japan’s public health infrastructure, including institutions like the National Institute of Infectious Diseases (NIID), is well-equipped for disease surveillance, outbreak response, and coordination of testing efforts.
•  
• The Japanese public is generally well-educated and informed about health issues, leading to higher compliance with public health measures and increased utilization of testing services of monkeypox.
   

UAE monkeypox testing market is anticipated to witness lucrative growth between 2024 – 2032.
 

• UAE has invested significantly in developing a modern and advanced healthcare infrastructure. State-of-the-art medical facilities and laboratories equipped with the latest diagnostic technologies enable high-quality and efficient monkeypox testing.
   
• The government has demonstrated a rapid response capability and preparedness for public health emergencies. The country’s swift action in setting up testing facilities and deploying resources during outbreaks has been exemplary, ensuring timely detection and management of monkeypox cases.
   

Monkeypox Testing Market Share

The monkeypox testing industry is highly competitive, marked by several players striving for market dominance. Providers offer comprehensive storage and analysis with improved efficiency and affordability. This includes advancements in processing, precision, automation, and customization. Competition is driven by factors such as the quality, reliability, and ease of usage along with integration capabilities with existing technologies, and compliance with regulatory standards. Strategic partnerships with companies and healthcare networks play a crucial role in market positioning.

Monkeypox Testing Market Companies

Some of the eminent market participants operating in the monkeypox testing industry include:

• Abbott Laboratories
• Aegis Sciences Corporation
• Applied DNA Sciences, Inc.
• Becton, Dickinson and Company
• BioGX
• bioMérieux SA
• Bio-Rad Laboratories, Inc.
• CerTest Biotec
• Creative Biogene
• Danaher Corporation
• Flow Health
• Laboratory Corporation of America Holdings
• Mayo Clinic Laboratories
• Quest Diagnostics, Inc.
• Thermo Fisher Scientific Inc.
   

Monkeypox Testing Industry News:

• In September 2022, Quest Diagnostics announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the company's lab-developed molecular diagnostic test to aid in the diagnosis of infection with the monkeypox virus. Thus, it expanded the product portfolio of the company and helped to generate revenue.
   
• In June 2022, CerTest Biotec collaborated with Becton, Dickinson and Company, and developed a molecular diagnostic test for the Monkeypox virus. As part of the collaboration, the assay and test leveraged the BD MAX open system reagent suite to validate the CerTest VIASURE Monkeypox CE/IVD molecular test on the BD MAX System. Thus, it created new horizon for the company and escalated the demands and sales.
   

The monkeypox testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Technology

• Polymerase chain reaction (PCR)
• Lateral flow assay (LFA)
• Other technologies

Market, By Mode

• Laboratory testing
• Point of care testing

Market, By End-use

• Hospitals and clinics
• Diagnostic laboratories
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa